Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Certara ( (CERT) ) has issued an update.
On May 21, 2025, Certara, Inc. held its annual stockholders meeting, where several key proposals were voted on. The stockholders elected four Class II directors to the board, ratified the selection of RSM US LLP as the independent auditor for 2025, and approved the executive compensation on a non-binding advisory basis. These decisions are crucial for Certara’s governance and operational strategies, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (CERT) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Certara stock, see the CERT Stock Forecast page.
Spark’s Take on CERT Stock
According to Spark, TipRanks’ AI Analyst, CERT is a Outperform.
Certara’s stock is bolstered by strong financial performance with efficient cash flow management and low leverage but faces challenges in profitability. The earnings call highlighted positive strategic initiatives and revenue growth. However, valuation concerns, particularly the negative P/E ratio, weigh down the score. Technical indicators suggest potential oversold conditions, which could present a buying opportunity despite recent bearish momentum.
To see Spark’s full report on CERT stock, click here.
More about Certara
Certara, Inc. operates in the pharmaceutical and biotechnology industry, providing software and services for drug development and regulatory science. The company focuses on enhancing decision-making in drug development through its biosimulation software and technology-driven solutions.
Average Trading Volume: 2,025,076
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.9B
See more data about CERT stock on TipRanks’ Stock Analysis page.